{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:34:38Z","timestamp":1794501278957,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T15:35:28Z","timestamp":1681832128000},"page":"3215-3223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Modelling the relative cost-effectiveness of the RTS,S\/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-9605","authenticated-orcid":false,"given":"Hillary M.","family":"Topazian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-0878","authenticated-orcid":false,"given":"Nora","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-8014","authenticated-orcid":false,"given":"Ines","family":"Gerard-Ursin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-1200","authenticated-orcid":false,"given":"Giovanni D.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-4910","authenticated-orcid":false,"given":"Azra C.","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3001-4959","authenticated-orcid":false,"given":"Peter","family":"Winskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.011_b0005","unstructured":"Global Technical Strategy for Malaria 2016-2030. Geneva; 2015."},{"key":"10.1016\/j.vaccine.2023.04.011_b0010","unstructured":"World Health Organization. Malaria vaccine: WHO position paper \u2013 March 2022. Weekly Epidemiological Record 2022; 9: 61\u201380."},{"key":"10.1016\/j.vaccine.2023.04.011_b0015","unstructured":"Gavi Board approves funding to support malaria vaccine roll-out in sub-Saharan Africa. Gavi, the Vaccine Alliance 2021. https:\/\/www.gavi.org\/news\/media-room\/gavi-board-approves-funding-support-malaria-vaccine-roll-out-sub-saharan-africa (accessed March 8, 2022)."},{"key":"10.1016\/j.vaccine.2023.04.011_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06120-9","article-title":"Population structure and diversity of Plasmodium falciparum in children with asymptomatic malaria living in different ecological zones of Ghana","volume":"21","author":"Amoah","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.011_b0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS, S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"Penny","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.011_b0030","first-page":"5","article-title":"Cost-effectiveness and public health impact of RTS, S\/AS01 E malaria vaccine in Malawi, using a Markov static model","author":"Ndeketa","year":"2020","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2023.04.011_b0035","article-title":"Economic impact of introducing the RTS, S malaria vaccine: cost-effectiveness and budget impact analysis in 41 countries","volume":"4","author":"Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.vaccine.2023.04.011_b0040","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1016\/j.vaccine.2020.04.031","article-title":"Case reduction and cost-effectiveness of the RTS, S\/AS01 malaria vaccine alongside bed nets in Lilongwe","volume":"38","author":"Bell","year":"2020","journal-title":"Malawi Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.011_b0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2016.11.042","article-title":"Country specific predictions of the cost-effectiveness of malaria vaccine RTS, S\/AS01 in endemic Africa","volume":"35","author":"Galactionova","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.011_b0050","doi-asserted-by":"crossref","first-page":"e000090","DOI":"10.1136\/bmjgh-2016-000090","article-title":"Modelling the cost-effectiveness of introducing the RTS, S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa","volume":"2","author":"Winskill","year":"2017","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0055","first-page":"4","article-title":"Reducing Malaria Mortality at the Lowest Budget: An Optimization Tool for Selecting Malaria Preventative Interventions Applied to Ghana","author":"Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.vaccine.2023.04.011_b0060","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(06)68440-7","article-title":"Advancement of global health: key messages from the Disease Control Priorities Project","volume":"367","author":"Laxminarayan","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.011_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2021.01.013","article-title":"Costs and cost-effectiveness of malaria control interventions: A systematic literature review","author":"Conteh","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0070","unstructured":"World malaria report 2020: 20 years of global progress and challenges. Geneva; 2020."},{"key":"10.1016\/j.vaccine.2023.04.011_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-021-03966-x","article-title":"Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage","volume":"20","author":"Unwin","year":"2021","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.04.011_b0080","unstructured":"UNICEF Supply Division. Malaria Vaccine: Questions and Answers on Vaccine Supply, Price, and Market Shaping August 2022. New York: 2022."},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.011_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sdata.2016.14","article-title":"A global bionomic database for the dominant vectors of human malaria","volume":"3","author":"Massey","year":"2016","journal-title":"Scientific Data"},{"key":"10.1016\/j.vaccine.2023.04.011_b0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ng1930","article-title":"A genome-wide map of diversity in Plasmodium falciparum","volume":"39","author":"Volkman","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.vaccine.2023.04.011_b0095","first-page":"18","article-title":"Poverty and food security: drivers of insecticide-treated mosquito net misuse in Malawi","author":"Berthe","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.04.011_b0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2471\/BLT.20.285369","article-title":"Improving malaria control by understanding human behaviour","volume":"99","author":"Monroe","year":"2021","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.04.011_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002448","article-title":"The US President\u2019s Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study","volume":"14","author":"Winskill","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.04.011_b0110","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/ncomms4136","article-title":"Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa","volume":"5","author":"Griffin","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.011_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000324","article-title":"Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies","volume":"7","author":"Griffin","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.04.011_b0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1756-3305-4-153","article-title":"Modelling the impact of vector control interventions on Anopheles gambiae population dynamics","volume":"4","author":"White","year":"2011","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2023.04.011_b0125","article-title":"Optimising the deployment of vector control tools against malaria: a data-informed modelling study","volume":"6","author":"Sherrard-Smith","year":"2022","journal-title":"Lancet Planet Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0130","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1086\/522985","article-title":"Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso","volume":"45","author":"Zongo","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.011_b0135","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.011_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-2755-5","article-title":"Prioritizing the scale-up of interventions for malaria control and elimination","volume":"18","author":"Winskill","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.04.011_b0145","unstructured":"WHO Guidelines for malaria - 14 March 2023. Geneva; 2023."},{"key":"10.1016\/j.vaccine.2023.04.011_b0150","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(19)31097-9","article-title":"Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"Weiss","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.011_b0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"Bhatt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.04.011_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-5-69","article-title":"A global map of dominant malaria vectors","volume":"5","author":"Sinka","year":"2012","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2023.04.011_b0165","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1038\/s41467-021-23707-7","article-title":"Maps and metrics of insecticide-treated net access, use, and nets-per-capita in Africa from 2000\u20132020","volume":"12","author":"Bertozzi-Villa","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.011_b0170","unstructured":"Health Organization W. Achieving and maintaining universal coverage with long-lasting insecticidal nets for malaria control. Geneva; 2017."},{"key":"10.1016\/j.vaccine.2023.04.011_b0175","unstructured":"WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa; 2012."},{"key":"10.1016\/j.vaccine.2023.04.011_b0180","first-page":"18","article-title":"Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case-control studies in 5 countries","author":"Cairns","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.04.011_b0185","unstructured":"Malaria Vaccine Implementation Programme (MVIP) Programme Advisory Group. Full Evidence Report on the RTS,S\/AS01 Malaria Vaccine. Geneva; 2021."},{"key":"10.1016\/j.vaccine.2023.04.011_b0190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.011_b0195","unstructured":"State of inequality: HIV, tuberculosis and malaria. Geneva; 2021."},{"key":"10.1016\/j.vaccine.2023.04.011_b0200","unstructured":"DHS-USAID. STATcompiler. The DHS Program. https:\/\/www.statcompiler.com\/en\/ (accessed June 16, 2022)."},{"key":"10.1016\/j.vaccine.2023.04.011_b0205","unstructured":"Life expectancy at birth (years) [Data table]. Geneva; 2020."},{"key":"10.1016\/j.vaccine.2023.04.011_b0210","first-page":"13","article-title":"Assessment of burden of malaria in Gwanda District, Zimbabwe, using the disability adjusted life years","author":"Gunda","year":"2016","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0215","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2214-109X(18)30422-4","article-title":"Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0220","unstructured":"Gavi. Malaria Vaccine Programme Investment Case: Report to the Board 30 November - 2 December 2021; 2021."},{"key":"10.1016\/j.vaccine.2023.04.011_b0225","first-page":"8","article-title":"Strengthening long-lasting insecticidal nets effectiveness monitoring using retrospective analysis of cross-sectional, population-based surveys across sub-Saharan Africa","author":"Janko","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.04.011_b0230","doi-asserted-by":"crossref","first-page":"e1325","DOI":"10.1016\/S2214-109X(21)00216-3","article-title":"Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance","volume":"9","author":"Lindsay","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0235","doi-asserted-by":"crossref","first-page":"e1003377","DOI":"10.1371\/journal.pmed.1003377","article-title":"Estimated impact of RTS, S\/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study","volume":"17","author":"Hogan","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.04.011_b0240","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2214-109X(16)30073-0","article-title":"Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study","volume":"4","author":"Walker","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.04.011_b0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12936-018-2183-y","article-title":"Effect of individual and community-level bed net usage on malaria prevalence among under-fives in the Democratic Republic of Congo","volume":"17","author":"Levitz","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.04.011_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.011_b0255","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S2214-109X(20)30475-7","article-title":"Seasonal malaria chemoprevention in the Sahel subregion of Africa: a cost-effectiveness and cost-savings analysis","volume":"9","author":"Gilmartin","year":"2021","journal-title":"Lancet Glob Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:19Z","timestamp":1759404439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003948"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the relative cost-effectiveness of the RTS,S\/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}